Laertis Ikonomou is an expert in Pulmonology at State University of New York (United States). Laertis Ikonomou has authored 59 publications, the most recent in 2026. SLR score: 205 (community average: 125). How the SLR is computed.

LeadR Profile

Laertis Ikonomou State University of New York United States
205 ScienceLeadR Reputation 205
Network Map

Pulmonology

Subspecialties: Biochemistry - Critical Care - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026

Source: PubMed

University at Buffalo - The State University of New York

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 59

Citations

Citations: 2 713 1st author: 15 Last author: 10 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Litigating the hype: the Lung Health Institute class action and its implications.
PMID 42556174 — cells, lung, microscopy, electron, scanning transmission, stem cells, cell transplantation
Cytotherapy20260
20 years of Progress in Stem Cells, Cell Therapy, and Bioengineering in Lung Biology and Diseases.
PMID 42286350 — cells, lung, bioengineering, microscopy, electron, scanning transmission, pluripotent stem cells, stem cells, therapeutics, tissues
Am J Respir Cell Mol Biol20260
Mapping cellular and ECM heterogeneity in pulmonary fibrosis - insights from recent spatiomics studies.
PMID 42183153 — cells, genes, fibrosis, pulmonary fibrosis, fibroblasts, tissues
Cell Biomater20260
Chemotherapy-Induced Oral Mucosal Injury Is Defined by p53 Activation, Cell Cycle Arrest and Diverse Epithelial Progenitor Dynamics.
PMID 41993375 — cells, genes, mouth mucosa, drug therapy, mucositis, fluorouracil, genes, p53, mucous membrane, cell cycle, chemotherapy
bioRxiv20260
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions.
PMID 40029229 — cells, genes, regenerative medicine, therapeutics, cell transplantation
Cytotherapy20250

LeadR Networks

Main global connection map